DAXAS 500micrograms Tablets/Film-coated

What is DAXAS 500micrograms

DAXAS 500 micrograms is a film-coated tablet that contains Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor. It is primarily indicated for the treatment of chronic obstructive pulmonary disease (COPD) and works by reducing inflammation in the lungs.

Roflumilast helps improve lung function and reduce the frequency of exacerbations in patients with COPD, making it an essential medication for managing this chronic condition.

How to use DAXAS 500micrograms

DAXAS 500 micrograms is taken orally. The usage instructions are as follows:

• Administration Route: The tablet should be swallowed whole with water, with or without food.
• Dosage Schedule: It is typically taken once daily, and adherence to the prescribed dosing regimen is crucial for optimal results.
• Missed Dose: If a dose is missed, take it as soon as possible. If it’s close to the next scheduled dose, skip the missed dose and continue with the regular dosing schedule.

Following these guidelines helps maximize the therapeutic benefits of DAXAS 500 micrograms.

Mode of Action DAXAS 500micrograms

DAXAS 500 micrograms exerts its therapeutic effects by inhibiting the enzyme phosphodiesterase-4 (PDE4), leading to increased levels of cyclic adenosine monophosphate (cAMP) in inflammatory cells. This results in a reduction of inflammatory mediators in the lungs.

• Mechanism of Action: By inhibiting PDE4, Roflumilast decreases inflammation and helps improve airflow in patients with COPD.
• Other Indications: It may also be used as an adjunct therapy in patients with frequent exacerbations.

DAXAS 500 micrograms is critical in the management of COPD, particularly in reducing inflammation and improving lung function.

DAXAS 500micrograms Interactions DAXAS 500micrograms

Before using DAXAS 500 micrograms, it is important to consider potential drug interactions:

• Other Respiratory Medications: Caution should be exercised when combining with other treatments for COPD to avoid potential additive effects.
• CYP450 Inhibitors: Concomitant use with strong CYP3A4 inhibitors may increase Roflumilast levels, requiring dosage adjustments.
• Consultation: Always discuss current medications with your healthcare provider before starting DAXAS 500 micrograms to avoid potential interactions.

Being aware of these interactions ensures the safe use of DAXAS 500 micrograms.

Dosage of DAXAS 500micrograms

The dosing for DAXAS 500 micrograms is as follows:

• Standard Dose: One tablet (500 micrograms) taken once daily.
• Adjustment: Dosage may be adjusted based on individual response and tolerability.
• Consultation: Always consult with your healthcare provider for appropriate dosing tailored to your condition.

Adjustments to the regimen may be necessary based on patient response.

Possible side effects of DAXAS 500micrograms

As with any medication, DAXAS 500 micrograms may cause side effects. Common side effects include:

• Diarrhea
• Nausea
• Headache
• Weight loss
• Insomnia

If severe side effects occur, such as persistent diarrhea or allergic reactions, seek medical attention promptly.

DAXAS 500micrograms Contraindications DAXAS 500micrograms

Information not available.

Storage of DAXAS 500micrograms

To preserve the stability and efficacy of DAXAS 500 micrograms, appropriate storage is essential:

• Store in a cool, dry place away from direct sunlight.
• Keep the medication out of reach of children.
• Do not use after its expiration date and dispose of any unused medication responsibly.

Proper storage helps maintain safety and efficacy.